A study published in Nature Genetics reports that loss of lineage fidelity underlies drug resistance in KRAS-mutant lung cancer.

What it means

This study, published in Nature Genetics, reveals that lung cancer cells with KRAS mutations can lose their normal cell identity (lineage fidelity) as a way to survive treatment and become drug-resistant. Using genetically engineered mouse models, the researchers show that this loss of lineage identity allows a subset of cells to persist during drug therapy and eventually drive resistance. The findings pinpoint a new mechanism—lineage plasticity—that could be targeted to overcome resistance in KRAS-mutant lung cancer.

Accuracy & sourcesSourced

The claim is based on a peer-reviewed primary research article in Nature Genetics, a top-tier journal. The study uses controlled mouse models and experimental data, so the conclusions are well-supported within that model system, though translation to human patients requires further validation.

How new